177 related articles for article (PubMed ID: 12094476)
1. Monitoring of cellular resistance to cancer chemotherapy.
Krishan A; Arya P
Hematol Oncol Clin North Am; 2002 Apr; 16(2):357-72, vi. PubMed ID: 12094476
[TBL] [Abstract][Full Text] [Related]
2. Drug retention, efflux, and resistance in tumor cells.
Krishan A; Fitz CM; Andritsch I
Cytometry; 1997 Dec; 29(4):279-85. PubMed ID: 9415409
[TBL] [Abstract][Full Text] [Related]
3. Transporter molecules in multidrug resistance.
Scheper RJ; Scheffer GL; Flens MJ; van der Valk P; Broxterman HJ; Izquierdo MA
Cytotechnology; 1996; 19(3):187-90. PubMed ID: 8862005
[No Abstract] [Full Text] [Related]
4. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
[TBL] [Abstract][Full Text] [Related]
5. Evidence of ABC transporters in fresh tumor cells from patients with ovarian cancer.
Sargent JM; Coley HM; Williamson C; Taylor C
Int J Clin Pharmacol Ther; 1998 Feb; 36(2):64-6. PubMed ID: 9520144
[No Abstract] [Full Text] [Related]
6. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.
Merlin JL; Bour-Dill C; Marchal S; Ramacci C; Poullain MG; Giroux B
Cytometry; 2000 Sep; 41(1):62-72. PubMed ID: 10942898
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
8. Novel mechanisms of drug resistance in leukemia.
Ross DD
Leukemia; 2000 Mar; 14(3):467-73. PubMed ID: 10720143
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistance in gliomas.
Lu C; Shervington A
Mol Cell Biochem; 2008 May; 312(1-2):71-80. PubMed ID: 18259841
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
11. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
13. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs.
Izquierdo MA; Scheffer GL; Flens MJ; Shoemaker RH; Rome LH; Scheper RJ
Cytotechnology; 1996; 19(3):191-7. PubMed ID: 8862006
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance: can new drugs help chemotherapy score against cancer?
Goldman B
J Natl Cancer Inst; 2003 Feb; 95(4):255-7. PubMed ID: 12591977
[No Abstract] [Full Text] [Related]
15. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells.
Meschini S; Calcabrini A; Monti E; Del Bufalo D; Stringaro A; Dolfini E; Arancia G
Int J Cancer; 2000 Sep; 87(5):615-28. PubMed ID: 10925353
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma.
Izquierdo MA; van der Zee AG; Vermorken JB; van der Valk P; Beliën JA; Giaccone G; Scheffer GL; Flens MJ; Pinedo HM; Kenemans P
J Natl Cancer Inst; 1995 Aug; 87(16):1230-7. PubMed ID: 7563169
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and clinical aspects of efflux pump related resistance to anti-cancer drugs.
Aszalos A; Ross DD
Anticancer Res; 1998; 18(4C):2937-44. PubMed ID: 9713488
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants.
Nüssler V; Pelka-Fleisc R; Gieseler F; Hasmann M; Löser R; Gullis E; Stötzer O; Zwierzina H; Wilmanns W
Leuk Lymphoma; 1998 Nov; 31(5-6):589-97. PubMed ID: 9922050
[TBL] [Abstract][Full Text] [Related]
20. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
